CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,809 enrolled
Drug / intervention
Edoxabandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02943993
NCT02943993N/ACompleted
CompareCT.gov

Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company·observational·Posted Oct 25, 2016·Updated Apr 1, 2025

In Brief

An observational study evaluating Edoxaban for Venous Thromboembolism. Completed, enrolled 2,809 participants across 1 site.

Detailed Summary

According to current guidelines, duration of anticoagulant treatment after a venous thromboembolic event varies from 3 months to indefinite treatment depending on the estimated risks of venous thromboembolism (VTE) recurrence and bleeding. Current data for edoxaban are limited to a maximum treatment duration of 12 months (Hokusai-VTE; N Engl J Med. 2013; 369:1406-15). Therefore, this study aims to gather further insight into efficacy (i.e. symptomatic recurrent VTE) and safety (i.e. bleeding events, liver adverse events, all-cause mortality and other drug related adverse events) of extended treatment with edoxaban up to 18 months in an unselected patient population in routine clinical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thromboembolism
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 25, 2016
Enrollment StartApr 6, 2016
Primary CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 9.7 years ago

Interventions

Edoxabandrug

Prescribed according to approved label